Armour Thyroid Geriatric (65+) Dosing: A Clinical Guide

Why Geriatric Dosing Differs From Standard Armour Thyroid Dosing

Older adults respond differently to thyroid hormone replacement than younger patients do. Cardiac sensitivity to T3 increases with age, and the clearance of both T4 and T3 slows as glomerular filtration rate declines. A dose that produces a TSH of 1.8 mIU/L in a 45-year-old may drive TSH below 0.5 mIU/L in an 80-year-old on the same regimen. Because Armour Thyroid contains both T4 and T3 in an approximately 4.2:1 ratio by weight [1], the direct T3 load is higher than with levothyroxine monotherapy, and that difference matters more in a patient with coronary artery disease or atrial fibrillation history.

Physiologic Changes That Drive Lower Dosing

Renal clearance of iodothyronines decreases progressively after age 60 [2]. Hepatic deiodination of T4 to T3 also slows, meaning the body retains circulating T3 longer. At the same time, beta-adrenergic receptor sensitivity to T3 increases in aging myocardium, raising the risk of tachyarrhythmia or angina at hormone levels that younger adults tolerate without difficulty.

Bone density is a second concern. Suppressed TSH, even mild suppression below 0.5 mIU/L, is associated with a two-fold increase in hip fracture risk in postmenopausal women [3]. Older men are not exempt. Any Armour Thyroid dose that consistently pushes TSH below the reference interval should be reduced or reconsidered.

Why NDT Raises Specific Geriatric Concerns

Natural desiccated thyroid products deliver a fixed T4:T3 ratio that cannot be separated. In a 70-year-old, the T3 component peaks in serum within two to four hours of ingestion and may produce transient palpitations, flushing, or anxiety [4]. These symptoms are often attributed to other causes in older patients. Splitting the daily dose, for example, 15 mg in the morning and 15 mg at midday, can blunt peak T3 excursions, though total daily exposure remains the same. Clinicians who use this split-dose strategy in geriatric patients should recheck TSH six weeks after any schedule change, not just after dose changes.

Recommended Starting Doses for Adults 65 and Older

The standard geriatric starting dose for Armour Thyroid is 15 mg to 30 mg once daily [5]. This is lower than the 60 mg starting dose that may be appropriate for younger adults with overt hypothyroidism. Patients older than 80, those with known cardiac disease, and those transitioning from long-standing untreated hypothyroidism should start at 15 mg and hold that dose for six full weeks before any upward adjustment.

Converting From Levothyroxine

Many older adults arrive at a geriatric care appointment already on levothyroxine, then ask about switching to Armour Thyroid. Conversion is not a simple milligram-for-milligram exchange. The general equivalence used in practice is that 60 mg (1 grain) of Armour Thyroid approximates 100 mcg of levothyroxine [6]. A patient stable on levothyroxine 75 mcg would convert to roughly 45 mg of Armour Thyroid. In practice, clinicians typically start 10 to 15% below the calculated equivalent and recheck TSH at four to six weeks.

A 2013 randomized crossover trial by Hoang et al. (J Clin Endocrinol Metab, N=70) compared NDT to levothyroxine over 16 weeks [7]. Both achieved similar TSH control. The NDT group showed modestly higher free T3 and slightly lower weight, and 49% of participants preferred NDT versus 19% preferring levothyroxine. The trial did not focus specifically on adults older than 65, so extrapolating preference data to the geriatric population requires caution.

Conversion From Other NDT Products

Armour Thyroid, NP Thyroid, and Nature-Throid are not bioequivalent by lot. If a patient switches brands, treat the change like a new start: recheck TSH in four to six weeks and do not assume prior stability transfers automatically [8].

Titration Protocol in the 65+ Population

Titration should proceed in increments of 15 mg no more frequently than every four to six weeks [5]. Younger adults are sometimes titrated every two to four weeks, but the older heart needs more time to adapt. The goal is the lowest dose that resolves hypothyroid symptoms and keeps TSH within the age-appropriate target range.

TSH Targets by Age Bracket

TSH targets shift upward with age:

• Adults 65 to 79: target TSH 1.0 to 4.0 mIU/L [9]
• Adults 80 and older: many endocrinology societies accept 4.0 to 7.0 mIU/L as safe [9]

The American Thyroid Association's 2014 guidelines note that in older adults, mild TSH elevation may represent physiologic adaptation and may not warrant aggressive treatment [9]. Chasing a TSH of 1.0 mIU/L in an 82-year-old increases the risk of atrial fibrillation and bone loss without proven cognitive or mortality benefit.

Monitoring Labs and Timing

Check TSH and free T4 six weeks after each dose change, not before. Free T3 is worth adding when a patient reports persistent symptoms despite normal TSH and free T4, because the T3 component of Armour Thyroid may produce an inappropriately elevated free T3 even when TSH appears adequate [4]. In a patient over 65 with cardiac history, an annual resting electrocardiogram is reasonable once a stable dose is reached.

Bone density screening follows standard USPSTF recommendations: dual-energy X-ray absorptiometry (DEXA) at least every two years in postmenopausal women and in men over 70 with risk factors [10]. Document baseline DEXA before starting any thyroid hormone replacement in a patient with osteopenia history, then recheck at two years.

Drug Interactions Relevant to Older Adults

Polypharmacy is common in the geriatric population, and Armour Thyroid has a meaningful interaction profile. Absorption is the primary concern.

Medications That Reduce Absorption

The following agents reduce NDT absorption when taken within four hours of the thyroid dose [6]:

• Calcium carbonate and calcium citrate (common in osteoporosis management)
• Ferrous sulfate and other iron salts
• Proton pump inhibitors (reduce gastric acid needed for tablet dissolution)
• Antacids containing aluminum or magnesium hydroxide
• Cholestyramine and colestipol
• Sucralfate

Older adults with osteoporosis may take calcium twice daily. Spacing calcium supplementation at least four hours from the morning Armour Thyroid dose is non-negotiable and must be documented in the care plan. The FDA prescribing information for levothyroxine products makes the same recommendation, and the same physiology applies to NDT [6].

Medications That Increase Thyroid Hormone Effect

Amiodarone inhibits peripheral conversion of T4 to T3 and displaces thyroid hormone from binding proteins [11]. In an older patient who starts amiodarone for atrial fibrillation while on stable Armour Thyroid, TSH may shift unpredictably in either direction. Recheck thyroid function within four to six weeks of any amiodarone initiation or dose change. Warfarin anticoagulation is also affected: thyroid hormone accelerates factor degradation, and patients on warfarin who change their Armour Thyroid dose may see INR rise [11]. Alert the anticoagulation clinic any time a thyroid dose is adjusted.

Drug-Nutrient Interactions

High-fiber diets and soy products may reduce T4 absorption by binding the hormone in the gut [8]. While the clinical magnitude is modest, a geriatric patient who starts a new high-soy protein supplement or a fiber regimen should have TSH rechecked within eight weeks.

Cardiac Considerations in Older Adults on NDT

Thyroid hormone has direct chronotropic and inotropic effects. In a patient with reduced left ventricular function or a history of angina, even a modest increase in free T3 can precipitate an adverse event. Armour Thyroid should be started at the lowest possible dose in any patient with:

• Ejection fraction below 40%
• Unstable angina or recent myocardial infarction within six months
• Persistent atrial fibrillation with rapid ventricular response
• Uncontrolled hypertension

A staged monitoring framework for high-cardiac-risk older adults starting NDT:

1. Baseline: Resting heart rate, blood pressure, ECG, TSH, free T4, free T3
2. Week 2: Symptom check by phone or patient portal; repeat heart rate and blood pressure
3. Week 6: Full thyroid panel; repeat ECG if baseline was abnormal
4. Week 12: Clinical visit; assess for angina, palpitations, edema
5. Week 24: DEXA if not done within prior 24 months; full metabolic panel

This staged approach reduces the risk of missing subclinical thyrotoxicosis in a population less likely to report classic symptoms.

Falls and Fracture Risk Management

Excess thyroid hormone raises osteoclast activity and decreases bone mineral density. A 2001 meta-analysis published in the Archives of Internal Medicine found that endogenous subclinical hyperthyroidism (TSH <0.1 mIU/L) was associated with a relative risk of hip fracture of 3.2 in postmenopausal women [3]. Exogenous thyroid hormone excess carries similar skeletal consequences.

Preventing TSH Suppression

Check TSH at every titration step. If TSH drops below 0.5 mIU/L in a patient older than 65, reduce the dose by one increment (15 mg) before the next scheduled assessment. Do not wait for symptoms. Asymptomatic TSH suppression in a geriatric patient is a prescribing error waiting to manifest as a wrist or hip fracture.

Fall Risk Assessment

Palpitations and resting tachycardia from excess T3 can contribute to orthostatic hypotension and dizziness, both of which increase fall risk [12]. At each visit, document resting heart rate and ask specifically about lightheadedness on standing. A heart rate consistently above 85 beats per minute at rest in an older patient on NDT warrants a thyroid panel before the next scheduled check.

Subclinical Hypothyroidism in Older Adults: When to Treat

Not all TSH elevations in older adults require treatment, and Armour Thyroid is not indicated for mild TSH elevation in this population without symptoms. The American Thyroid Association's position is that treatment of subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) in adults older than 65 should be individualized [9]. The TRUST trial (N=737, adults older than 65 with subclinical hypothyroidism) found no difference in hypothyroid symptoms or quality of life between levothyroxine and placebo at one year [13]. NDT was not studied in TRUST, but the finding challenges the assumption that normalizing TSH in older adults always produces clinical benefit.

When Treatment Is Appropriate

Treat subclinical hypothyroidism with any thyroid hormone product, including NDT, in older adults who have:

• TSH persistently above 10 mIU/L on two separate measurements
• Clear hypothyroid symptoms (fatigue, cold intolerance, constipation, cognitive slowing) with TSH above the reference interval
• A strong personal or family history of autoimmune thyroid disease with rising anti-TPO antibodies

Conversely, an asymptomatic 78-year-old with TSH of 5.8 mIU/L on repeat testing may be observed rather than treated, reserving Armour Thyroid or any thyroid product for those who develop symptoms [9].

Deprescribing Armour Thyroid in Older Adults

Deprescribing, the planned, supervised reduction or discontinuation of a medication, applies to thyroid hormone in specific geriatric scenarios. A patient who started NDT decades ago for fatigue without a documented TSH elevation at the time of initiation may not have true hypothyroidism. Thyroid reserve can also recover partially in some autoimmune thyroid disease patterns.

Criteria for Considering Dose Reduction

Consider stepwise reduction of Armour Thyroid in older adults when:

• TSH is persistently below 0.5 mIU/L despite standard dosing
• The original indication for therapy is undocumented or questionable
• New cardiac or bone disease makes the risk-benefit ratio unfavorable
• The patient is older than 80 and frail, with TSH consistently in the low-normal range

Reduction proceeds in 15 mg decrements every six weeks, with TSH checked before each step down. Abrupt discontinuation is not recommended because it can trigger a rebound hypothyroid state with symptoms more pronounced than the baseline condition [5].

Documenting the Deprescribing Plan

Every reduction should be documented with a clear clinical rationale in the chart. Include the target TSH range, the monitoring schedule, and the conditions under which reduction would be paused or reversed. This protects the patient and the prescribing clinician if thyroid function deteriorates.

Practical Administration Tips for Geriatric Patients

Timing and Food

Armour Thyroid tablets should be taken on an empty stomach, 30 to 60 minutes before the first meal of the day [5]. For older adults who take morning medications with food, the thyroid tablet should be separated from that routine. Some patients find it easier to take NDT immediately upon waking, before getting out of bed, to ensure the dose is not forgotten or combined with food inadvertently.

Swallowing and Tablet Form

Armour Thyroid tablets are small and can be chewed or swallowed whole [5]. For older adults with swallowing difficulty (dysphagia), chewing the tablet is an acceptable alternative. Compounded NDT preparations in liquid or smaller tablet form are available through some compounding pharmacies, though these are not FDA-regulated products and their bioavailability may vary.

Storage and Supply

Desiccated thyroid products are susceptible to humidity and heat. Tablets should be stored at room temperature (15 to 30°C) away from moisture [5]. Older adults living in humid climates or who store medications in bathrooms should be counseled specifically on this point.

Special Populations Within the Geriatric Group

Patients With Chronic Kidney Disease

CKD reduces iodothyronine clearance and may cause falsely low TSH independent of thyroid function. In patients with an estimated GFR below 30 mL/min/1.73 m², interpret TSH results alongside clinical symptoms and free T4 before adjusting NDT doses. Starting doses at the lower end of the geriatric range (15 mg) are appropriate, and titration should proceed more slowly [2].

Patients With Cognitive Impairment

Both hypothyroidism and hyperthyroidism worsen cognitive function. In a patient with dementia on Armour Thyroid, family members or caregivers should be incorporated into adherence monitoring. Missed doses followed by double-dosing create erratic TSH fluctuations that are difficult to interpret and can produce anxiety, agitation, or behavioral changes that are misattributed to the dementia itself.

Post-Thyroidectomy Older Adults

Older adults who are post-total thyroidectomy are fully dependent on exogenous thyroid hormone and cannot tolerate extended periods of underreplacement. The monitoring interval remains six weeks after any dose change, but clinicians should be alert to the fact that these patients have no thyroid reserve to buffer dose errors. Free T4 rather than TSH alone is the primary monitoring target in the first months after thyroidectomy, because TSH normalization lags behind tissue T4 restoration by several weeks [14].

Comparing NDT to Levothyroxine in Older Adults: What the Evidence Shows

Levothyroxine remains the most commonly prescribed thyroid hormone product and the one with the most geriatric-specific data. The 2013 Hoang trial (N=70) remains the most cited randomized comparison of NDT and levothyroxine, finding similar TSH control and a patient preference signal toward NDT [7]. A 2019 systematic review in Thyroid (Idrees et al.) identified no randomized trial with a geriatric-specific primary outcome comparing NDT to levothyroxine [15]. This gap in evidence does not mean NDT is unsafe in older adults. It means the prescriber must apply physiologic reasoning, careful monitoring, and individualized judgment in the absence of a large geriatric-focused RCT.

The direct T3 content of NDT may benefit older adults whose peripheral T4-to-T3 conversion is impaired, a common finding with age-related decline in deiodinase activity [4]. Whether that biochemical difference translates into symptom or quality-of-life benefit has not been demonstrated in a trial powered for geriatric outcomes.